{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:16:13Z","timestamp":1792977373129,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Major depressive disorder is one of the most common psychiatric disorders, which is associated with a high disease burden. Current treatments using antidepressants have limitations, so using medication with neuromodulating and anti-inflammatory properties alongside them could be helpful. In a clinical trial, we studied the effectiveness of empagliflozin, a blood sugar-lowering drug, as an adjunctive therapy to reduce the severity of depression symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A number of outpatients with moderate to severe depression (Hamilton Depression Rating Scale (HDRS)\u2009&gt;\u2009=\u200917) who were not under related medication or had not taken medication for at least the last two months, had an age range of 18\u201360 years and had written informed consent to enter the study (<jats:italic>N<\/jats:italic>\u2009=\u200990) were randomly divided into two groups receiving placebo or empagliflozin (10\u00a0mg daily) combined with citalopram (40\u00a0mg daily) based on permuted block randomization method in an 8-week randomized, double-blind, placebo-controlled clinical trial. They were evaluated using the HDRS in weeks 0, 4, and 8.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HDRS scores were equal to 28.42(\u00b1\u20093.83), 20.20(\u00b1\u20093.82), and 13.42(\u00b1\u20093.42) in the placebo group during weeks 0,4, and 8, respectively. These scores were 27.36(\u00b1\u20093.77), 13.76(\u00b1\u20091.40), and 7.00(\u00b1\u20091.13), respectively, for the group treated with empagliflozin. Compared to the control group, patients treated with empagliflozin using repeated-measures ANOVA showed greater improvement in reducing the severity of depression symptoms over time (<jats:italic>p<\/jats:italic> value\u2009=\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Considering the promising findings in this clinical trial, further study of empagliflozin as adjunctive therapy in MDD with larger sample sizes and longer follow-ups is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-05627-0","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:02:11Z","timestamp":1708927331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-1734","authenticated-orcid":false,"given":"Atefeh","family":"Zandifar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-1678","authenticated-orcid":false,"given":"Rahim","family":"Badrfam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-7588","authenticated-orcid":false,"given":"Mostafa","family":"Qorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"5627_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1590\/1516-4446-2020-0650","volume":"42","author":"L Guti\u00e9rrez-Rojas","year":"2020","unstructured":"Guti\u00e9rrez-Rojas L, Porras-Segovia A, Dunne H, Andrade-Gonz\u00e1lez N, Cervilla JA. Prevalence and correlates of major depressive disorder: a systematic review. Brazilian J Psychiatry. 2020;42:657\u201372.","journal-title":"Brazilian J Psychiatry"},{"issue":"15","key":"5627_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153377","volume":"10","author":"A Mosio\u0142ek","year":"2021","unstructured":"Mosio\u0142ek A, Mosio\u0142ek J, Jakima S, Pi\u0119ta A, Szulc A. Effects of antidepressant treatment on neurotrophic factors (BDNF and IGF-1) in patients with major depressive disorder (MDD). J Clin Med. 2021;10(15): 3377.","journal-title":"J Clin Med"},{"key":"5627_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fpsyt.2019.00145","volume":"10","author":"HG Ruhe","year":"2019","unstructured":"Ruhe HG, Mocking RJ, Figueroa CA, Seeverens PW, Ikani N, Tyborowska A, et al. Emotional biases and recurrence in major depressive disorder. Results of 2.5 years follow-up of drug-free cohort vulnerable for recurrence. Front Psychiatry. 2019;10:145.","journal-title":"Front Psychiatry"},{"issue":"10189","key":"5627_CR4","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S0140-6736(18)32408-5","volume":"393","author":"H Herrman","year":"2019","unstructured":"Herrman H, Kieling C, McGorry P, Horton R, Sargent J, Patel V. Reducing the global burden of depression: a Lancet\u2013World Psychiatric Association Commission. Lancet. 2019;393(10189):e42\u20133.","journal-title":"Lancet"},{"issue":"8","key":"5627_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2020.1107","volume":"77","author":"MG Harris","year":"2020","unstructured":"Harris MG, Kazdin AE, Chiu WT, Sampson NA, Aguilar-Gaxiola S, Al-Hamzawi A, et al. Findings from world mental health surveys of the perceived helpfulness of treatment for patients with major depressive disorder. JAMA Psychiat. 2020;77(8):830\u201341.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"5627_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/13651501.2020.1782433","volume":"24","author":"M Ghaffari Darab","year":"2020","unstructured":"Ghaffari Darab M, Hedayati A, Khorasani E, Bayati M, Keshavarz K. Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews. Int J Psychiatry Clin Pract. 2020;24(4):357\u201370.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"5627_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.reprotox.2020.11.013","volume":"99","author":"SM Hutchison","year":"2021","unstructured":"Hutchison SM, M\u00e2sse LC, Pawluski JL, Oberlander TF. Perinatal selective serotonin reuptake inhibitor (SSRI) and other antidepressant exposure effects on anxiety and depressive behaviors in offspring: a review of findings in humans and rodent models. Reprod Toxicol. 2021;99:80\u201395.","journal-title":"Reprod Toxicol"},{"key":"5627_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpsychires.2019.04.005","volume":"114","author":"B Zhao","year":"2019","unstructured":"Zhao B, Li Z, Wang Y, Ma X, Wang X, Wang X, et al. Manual or electroacupuncture as an add-on therapy to SSRIs for depression: a randomized controlled trial. J Psychiatr Res. 2019;114:24\u201333.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"5627_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/acps.13235","volume":"142","author":"C Braun","year":"2020","unstructured":"Braun C, Adams A, Rink L, Bschor T, Kuhr K, Baethge C. In search of a dose\u2013response relationship in SSRIs\u2014a systematic review, meta-analysis, and network meta\u2010analysis. Acta Psychiatr Scand. 2020;142(6):430\u201342.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"5627_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","volume":"6","author":"TA Furukawa","year":"2019","unstructured":"Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"5627_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ejn.14630","volume":"53","author":"RS Duman","year":"2021","unstructured":"Duman RS, Deyama S, Foga\u00e7a MV. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid\u2010acting antidepressants. Eur J Neurosci. 2021;53(1):126\u201339.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"5627_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1734-1140(13)71517-2","volume":"65","author":"M Siwek","year":"2013","unstructured":"Siwek M, Sowa-Ku\u0107ma M, Dudek D, Stycze\u0144 K, Szewczyk B, Kotarska K, et al. Oxidative stress markers in affective disorders. Pharmacol Rep. 2013;65(6):1558\u201371.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"5627_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22\u201334.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5627_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/YCO.0000000000000905","volume":"37","author":"AJ Krupa","year":"2024","unstructured":"Krupa AJ, Dudek D, Siwek M. Consolidating evidence on the role of insulin resistance in major depressive disorder. Curr Opin Psychiatry. 2024;37(1):23\u20138.","journal-title":"Curr Opin Psychiatry"},{"key":"5627_CR15","doi-asserted-by":"publisher","first-page":"104758","DOI":"10.1016\/j.neubiorev.2022.104758","volume":"139","author":"BS Fernandes","year":"2022","unstructured":"Fernandes BS, Salagre E, Enduru N, Grande I, Vieta E, Zhao Z. Insulin resistance in depression: a large meta-analysis of metabolic parameters and variation. Neurosci Biobehav Rev. 2022;139:104758.","journal-title":"Neurosci Biobehav Rev"},{"key":"5627_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.brainresbull.2018.12.015","volume":"146","author":"P Dome","year":"2019","unstructured":"Dome P, Tombor L, Lazary J, Gonda X, Rihmer Z. Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Res Bull. 2019;146:51\u201378.","journal-title":"Brain Res Bull"},{"issue":"1","key":"5627_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/jnnp-2019-320912","volume":"91","author":"S Bai","year":"2020","unstructured":"Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(1):21\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5627_CR18","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13311-020-00878-7","volume":"17","author":"MS Abdallah","year":"2020","unstructured":"Abdallah MS, Mosalam EM, Zidan A-AA, Elattar KS, Zaki SA, Ramadan AN, et al. The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: a proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics. 2020;17:1897\u2013906.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"5627_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/npp.2012.58","volume":"37","author":"K Sepanjnia","year":"2012","unstructured":"Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia M-J, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37(9):2093\u2013100.","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"5627_CR20","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","volume":"117","author":"YJ Chung","year":"2021","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H\u2009+\u2009exchanger-1 or lower [Na+] i in the heart. Cardiovascular Res. 2021;117(14):2794\u2013806.","journal-title":"Cardiovascular Res"},{"key":"5627_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.758080","volume":"12","author":"Y Tan","year":"2021","unstructured":"Tan Y, Yu K, Liang L, Liu Y, Song F, Ge Q, et al. Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function after cardiac arrest in rats by enhancing mitochondrial energy metabolism. Front Pharmacol. 2021;12: 758080.","journal-title":"Front Pharmacol"},{"issue":"2","key":"5627_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40200-021-00874-4","volume":"20","author":"M Jamalizadeh","year":"2021","unstructured":"Jamalizadeh M, Hasanzad M, Sarhangi N, Sharifi F, Nasli-Esfahani E, Larijani B. Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients. J Diabetes Metab Disorders. 2021;20(2):1407\u201313.","journal-title":"J Diabetes Metab Disorders"},{"issue":"5","key":"5627_CR23","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.52711\/0974-360X.2022.00395","volume":"15","author":"S Arun","year":"2022","unstructured":"Arun S, Praveen D, Chowdary RP, Aanandhi VM. A Comprehensive Review on Sodium glucose co-transporter-2 inhibitors-Empagliflozin. Res J Pharm Technol. 2022;15(5):2376\u201380.","journal-title":"Res J Pharm Technol"},{"issue":"15","key":"5627_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5627_CR25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384\u201395.","journal-title":"Circulation"},{"key":"5627_CR26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","volume":"43","author":"RG Abdel-Latif","year":"2020","unstructured":"Abdel-Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway. Arch Pharm Res. 2020;43:514\u201325.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"5627_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/fcp.12548","volume":"34","author":"EF Amin","year":"2020","unstructured":"Amin EF, Rifaai RA, Abdel-latif RG. Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative\u2013inflammatory\u2013apoptotic pathway. Fundam Clin Pharmacol. 2020;34(5):548\u201358.","journal-title":"Fundam Clin Pharmacol"},{"key":"5627_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2147\/DDDT.S351421","volume":"Volume 16","author":"Y Li","year":"2022","unstructured":"Li Y, Wang M-L, Zhang B, Fan X-X, Tang Q, Yu X, et al. Antidepressant-like effect and mechanism of ginsenoside rd on rodent models of depression. Drug Des Dev Ther. 2022;Volume 16:843\u201361.","journal-title":"Drug Des Dev Ther"},{"key":"5627_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.968124","volume":"13","author":"X-X Fan","year":"2022","unstructured":"Fan X-X, Sun W-Y, Li Y, Tang Q, Li L-N, Yu X, et al. Honokiol improves depression-like behaviors in rats by HIF-1\u03b1-VEGF signaling pathway activation. Front Pharmacol. 2022;13: 968124.","journal-title":"Front Pharmacol"},{"key":"5627_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2019.100088","volume":"14","author":"K Kobayashi","year":"2019","unstructured":"Kobayashi K, Toyoda M, Hatori N. Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus. Obes Med. 2019;14: 100088.","journal-title":"Obes Med"},{"key":"5627_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.psychres.2018.09.047","volume":"270","author":"KW Choi","year":"2018","unstructured":"Choi KW, Na EJ, Fava M, Mischoulon D, Cho H, Jeon HJ. Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder. Psychiatry Res. 2018;270:246\u201352.","journal-title":"Psychiatry Res"},{"issue":"1","key":"5627_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0018-506X(02)00016-8","volume":"43","author":"KJ Parker","year":"2003","unstructured":"Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav. 2003;43(1):60\u20136.","journal-title":"Horm Behav"},{"issue":"45","key":"5627_CR33","doi-asserted-by":"publisher","first-page":"e27638","DOI":"10.1097\/MD.0000000000027638","volume":"100","author":"T Higashikawa","year":"2021","unstructured":"Higashikawa T, Ito T, Mizuno T, Ishigami K, Kuroki K, Maekawa N, et al. Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: a retrospective study of a patient cohort. Medicine. 2021;100(45):e27638.","journal-title":"Medicine"},{"issue":"2","key":"5627_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","volume":"107","author":"E Beurel","year":"2020","unstructured":"Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234\u201356.","journal-title":"Neuron"},{"issue":"19","key":"5627_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193107","volume":"11","author":"M Heimke","year":"2022","unstructured":"Heimke M, Lenz F, Rickert U, Lucius R, Cossais F. Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary Microglia. Cells. 2022;11(19): 3107.","journal-title":"Cells"},{"key":"5627_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117908","volume":"256","author":"AM Abdelhamid","year":"2020","unstructured":"Abdelhamid AM, Elsheakh AR, Abdelaziz RR, Suddek GM. Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-\u03baB\/Nrf-2\/PPAR-\u03b3 interplay in mice. Life Sci. 2020;256: 117908.","journal-title":"Life Sci"},{"key":"5627_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00213-020-05699-2","volume":"238","author":"X-q Wang","year":"2021","unstructured":"Wang X-q, Tang Y-h, Zeng G-r, Wu L-f, Zhou Y-j, Cheng Z-n, et al. Carnosic acid alleviates depression-like behaviors on chronic mild stressed mice via PPAR-\u03b3-dependent regulation of ADPN\/FGF9 pathway. Psychopharmacology. 2021;238:501\u201316.","journal-title":"Psychopharmacology"},{"issue":"21","key":"5627_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900243","volume":"63","author":"L Cigliano","year":"2019","unstructured":"Cigliano L, Spagnuolo MS, Boscaino F, Ferrandino I, Monaco A, Capriello T, et al. Dietary supplementation with fish oil or conjugated linoleic acid relieves depression markers in mice by modulation of the Nrf2 pathway. Mol Nutr Food Res. 2019;63(21): 1900243.","journal-title":"Mol Nutr Food Res"},{"key":"5627_CR39","doi-asserted-by":"publisher","first-page":"174993","DOI":"10.1016\/j.ejphar.2022.174993","volume":"925","author":"R Subba","year":"2022","unstructured":"Subba R, Ahmad MH, Ghosh B, Mondal AC. Targeting NRF2 in type 2 diabetes mellitus and depression: efficacy of natural and synthetic compounds. Eur J Pharmacol. 2022;925:174993.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"5627_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3906\/sag-2008-37","volume":"51","author":"S \u015eahin","year":"2021","unstructured":"\u015eahin S, Halilo\u011flu \u00d6, Korkmaz \u00d6P, Durcan E, \u015eah\u0130n HR, Yumuk VD, et al. Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleepquality, quality of life, and anxiety levels in people with type 2 diabetes mellitus? Turk J Med Sci. 2021;51(2):735\u201342.","journal-title":"Turk J Med Sci"},{"issue":"1","key":"5627_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-020-00561-0","volume":"20","author":"CK Klarskov","year":"2020","unstructured":"Klarskov CK, Holm Schultz H, Persson F, M\u00f8ller Christensen T, Almdal TP, Snorgaard O, et al. Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH insulin for sTeroId diAbeTEs)-a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. BMC Endocr Disorders. 2020;20(1):1\u201311.","journal-title":"BMC Endocr Disorders"},{"issue":"8","key":"5627_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","volume":"45","author":"JB Williams","year":"1988","unstructured":"Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"5627_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF03035120","volume":"251","author":"JB Williams","year":"2001","unstructured":"Williams JB. Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin NeuroSci. 2001;251:6\u201312.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"issue":"11","key":"5627_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259861","volume":"16","author":"C Fenton","year":"2021","unstructured":"Fenton C, McLoughlin DM. Usefulness of Hamilton rating scale for depression subset scales and full versions for electroconvulsive therapy. PLoS ONE. 2021;16(11): e0259861.","journal-title":"PLoS ONE"},{"issue":"4","key":"5627_CR45","first-page":"251","volume":"4","author":"A Akdemir","year":"1996","unstructured":"Akdemir A, \u00d6rsel DS, Da\u011f \u0130, T\u00fcrk\u00e7apar MH. Hamilton depresyon derecelendirme \u00f6l\u00e7e\u011fi (HDD\u00d6)\u2019nin ge\u00e7erlili\u011fi-g\u00fcvenirlili\u011fi ve klinikte kullan\u0131m\u0131. Psikiyatri Psikoloji Psikofarmakoloji Dergisi. 1996;4(4):251\u20139.","journal-title":"Psikiyatri Psikoloji Psikofarmakoloji Dergisi"},{"issue":"1","key":"5627_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1): 56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"5627_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384\u20138.","journal-title":"J Affect Disord"},{"issue":"11","key":"5627_CR48","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1176\/appi.ajp.161.11.2050","volume":"161","author":"SP Roose","year":"2004","unstructured":"Roose SP, Sackeim HA, Krishnan KRR, Pollock BG, Alexopoulos G, Lavretsky H, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry. 2004;161(11):2050\u20139.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"5627_CR49","first-page":"328","volume":"13","author":"A Sadeghi","year":"2023","unstructured":"Sadeghi A, Ghorayshi F, Baghshahi H, Akbari H, Memarzadeh MR, Taghizadeh M, et al. The antidepressant effect of combined extracts of Hypericum perforatum and Echium amoenum supplementation in patients with depression symptoms: a randomized clinical trial. Avicenna J Phytomed. 2023;13(4):328\u201337.","journal-title":"Avicenna J Phytomed"},{"issue":"8","key":"5627_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.brat.2013.05.006","volume":"51","author":"L Moradveisi","year":"2013","unstructured":"Moradveisi L, Huibers MJ, Renner F, Arasteh M, Arntz A. The influence of comorbid personality disorder on the effects of behavioural activation vs. antidepressant medication for major depressive disorder: results from a randomized trial in Iran. Behav Res Ther. 2013;51(8):499\u2013506.","journal-title":"Behav Res Ther"},{"issue":"3","key":"5627_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/gastro\/gou091","volume":"3","author":"M Mirabdolhagh Hazaveh","year":"2015","unstructured":"Mirabdolhagh Hazaveh M, Dormohammadi Toosi T, Nasiri Toosi M, Tavakoli A, Shahbazi F. Prevalence and severity of depression in chronic viral hepatitis in Iran. Gastroenterol Rep. 2015;3(3):234\u20137.","journal-title":"Gastroenterol Rep"},{"issue":"3","key":"5627_CR52","first-page":"6063","volume":"7","author":"S Baghestani","year":"2015","unstructured":"Baghestani S, Zare S, Seddigh SH. Severity of depression and anxiety in patients with Alopecia Areata in Bandar Abbas Iran. Dermatology Rep. 2015;7(3):6063.","journal-title":"Dermatology Rep"},{"key":"5627_CR53","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/DMSO.S249385","volume":"13","author":"T Dehesh","year":"2020","unstructured":"Dehesh T, Dehesh P, Shojaei S. Prevalence and associated factors of anxiety and depression among patients with type 2 diabetes in Kerman, Southern Iran. Diabetes Metab Syndr Obesity. 2020;13:1509.","journal-title":"Diabetes Metab Syndr Obesity"},{"issue":"2","key":"5627_CR54","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.psychres.2015.10.022","volume":"230","author":"D Ashoorian","year":"2015","unstructured":"Ashoorian D, Davidson R, Rock D, Dragovic M, Clifford R. A clinical communication tool for the assessment of psychotropic medication side effects. Psychiatry Res. 2015;230(2):643\u201357.","journal-title":"Psychiatry Res"},{"issue":"1","key":"5627_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65\u201378.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"5627_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/eip.12127","volume":"9","author":"SE Hetrick","year":"2015","unstructured":"Hetrick SE, Dellosa MK, Simmons MB, Phillips L. Development and pilot testing of an online monitoring tool of depression symptoms and side effects for young people being treated for depression. Early Interv Psychiat. 2015;9(1):66\u20139.","journal-title":"Early Interv Psychiat"},{"issue":"12","key":"5627_CR57","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1039\/C9RA08442H","volume":"10","author":"JW Manoel","year":"2020","unstructured":"Manoel JW, Primieri GB, Bueno LM, Wingert NR, Volpato NM, Garcia CV, et al. The application of quality by design in the development of the liquid chromatography method to determine empagliflozin in the presence of its organic impurities. RSC Adv. 2020;10(12):7313\u201320.","journal-title":"RSC Adv"},{"key":"5627_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"5627_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"T Heise","year":"2013","unstructured":"Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Therapy. 2013;4:331\u201345.","journal-title":"Diabetes Therapy"},{"issue":"21","key":"5627_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213372","volume":"11","author":"KI Avgerinos","year":"2022","unstructured":"Avgerinos KI, Mullins RJ, Vreones M, Mustapic M, Chen Q, Melvin D, et al. Empagliflozin Induced Ketosis, upregulated IGF-1\/Insulin receptors and the Canonical Insulin Signaling Pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics. Cells. 2022;11(21): 3372.","journal-title":"Cells"},{"key":"5627_CR61","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022050623","author":"J Refardt","year":"2022","unstructured":"Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, et al. Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol. 2022. https:\/\/doi.org\/10.1681\/ASN.2022050623. (ASN . 2022050623).","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5627_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/1744-9987.13395","volume":"24","author":"SS Fan","year":"2020","unstructured":"Fan SS, Lin LF, Chen VCH, Hsieh CW, Hsiao HP, McIntyre RS, et al. Effects of Lower Past-Year serum sodium and hyponatremia on depression symptoms and cognitive impairments in patients with hemodialysis. Ther Apher Dial. 2020;24(2):169\u201377.","journal-title":"Ther Apher Dial"},{"key":"5627_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-020-01955-4","volume":"21","author":"C Fujisawa","year":"2021","unstructured":"Fujisawa C, Umegaki H, Sugimoto T, Samizo S, Huang CH, Fujisawa H, et al. Mild hyponatremia is associated with low skeletal muscle mass, physical function impairment, and depressive mood in the elderly. BMC Geriatr. 2021;21:1\u20138.","journal-title":"BMC Geriatr"},{"issue":"19","key":"5627_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195810","volume":"11","author":"G-H Kim","year":"2022","unstructured":"Kim G-H. Pathophysiology of Drug-Induced Hyponatremia. J Clin Med. 2022;11(19): 5810.","journal-title":"J Clin Med"},{"issue":"8","key":"5627_CR65","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/02698811211001082","volume":"35","author":"B Mannheimer","year":"2021","unstructured":"Mannheimer B, Falhammar H, Calissendorff J, Skov J, Lindh JD. Time-dependent association between selective serotonin reuptake inhibitors and hospitalization due to hyponatremia. J Psychopharmacol. 2021;35(8):928\u201333.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"5627_CR66","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1038\/s41467-020-16090-2","volume":"11","author":"J Michely","year":"2020","unstructured":"Michely J, Eldar E, Martin IM, Dolan RJ. A mechanistic account of serotonin\u2019s impact on mood. Nat Commun. 2020;11(1):2335.","journal-title":"Nat Commun"},{"issue":"4","key":"5627_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.maturitas.2013.08.010","volume":"76","author":"CK Mannesse","year":"2013","unstructured":"Mannesse CK, Jansen PA, Van Marum RJ, Sival RC, Kok RM, Haffmans PJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357\u201363.","journal-title":"Maturitas"},{"issue":"6","key":"5627_CR68","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.psym.2014.01.010","volume":"55","author":"L De Picker","year":"2014","unstructured":"De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536\u201347.","journal-title":"Psychosomatics"},{"key":"5627_CR69","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00406-017-0778-x","volume":"268","author":"M Bogren","year":"2018","unstructured":"Bogren M, Br\u00e5dvik L, Holmstrand C, N\u00f6bbelin L, Mattisson C. Gender differences in subtypes of depression by first incidence and age of onset: a follow-up of the Lundby population. Eur Arch Psychiatry Clin NeuroSci. 2018;268:179\u201389.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"key":"5627_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00450","volume":"9","author":"JC Tolentino","year":"2018","unstructured":"Tolentino JC, Schmidt SL. DSM-5 criteria and depression severity: implications for clinical practice. Front Psychiatry. 2018;9: 450.","journal-title":"Front Psychiatry"},{"issue":"10","key":"5627_CR71","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2215-0366(21)00362-X","volume":"8","author":"E Bryant","year":"2021","unstructured":"Bryant E. Anorexia: the great taboo. Lancet Psychiatry. 2021;8(10):866\u20137.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"5627_CR72","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1196\/annals.1300.016","volume":"1003","author":"IA Paul","year":"2003","unstructured":"Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003;1003(1):250\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5627_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102(1):75\u201390.","journal-title":"Neuron"},{"key":"5627_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109668","volume":"94","author":"M Amidfar","year":"2019","unstructured":"Amidfar M, Woelfer M, Reus GZ, Quevedo J, Walter M, Kim Y-K. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94: 109668.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"5627_CR75","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/jnr.25022","volume":"100","author":"J Keifer","year":"2022","unstructured":"Keifer J. Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease. J Neurosci Res. 2022;100(4):979\u201391.","journal-title":"J Neurosci Res"},{"key":"5627_CR76","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/NDT.S227598","volume":"16","author":"C Chen","year":"2020","unstructured":"Chen C, Dong Y, Liu F, Gao C, Ji C, Dang Y, et al. A study of antidepressant effect and mechanism on intranasal delivery of BDNF-HA2TAT\/AAV to rats with post-stroke depression. Neuropsychiatr Dis Treat. 2020;16:637\u201349.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"5627_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopsych.2021.05.008","volume":"90","author":"E Castr\u00e9n","year":"2021","unstructured":"Castr\u00e9n E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90(2):128\u201336.","journal-title":"Biol Psychiatry"},{"issue":"20","key":"5627_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207777","volume":"21","author":"L Colucci-D\u2019Amato","year":"2020","unstructured":"Colucci-D\u2019Amato L, Speranza L, Volpicelli F. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci. 2020;21(20): 7777.","journal-title":"Int J Mol Sci"},{"key":"5627_CR79","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s12031-020-01754-x","volume":"71","author":"T Rana","year":"2021","unstructured":"Rana T, Behl T, Sehgal A, Srivastava P, Bungau S. Unfolding the role of BDNF as a biomarker for treatment of Depression. J Mol Neurosci. 2021;71:2008\u201321.","journal-title":"J Mol Neurosci"},{"key":"5627_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121258","volume":"312","author":"HH Mousa","year":"2023","unstructured":"Mousa HH, Sharawy MH, Nader MA. Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: role of BDNF, CREB and Npas4. Life Sci. 2023;312: 121258.","journal-title":"Life Sci"},{"key":"5627_CR81","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1134\/S0006297917030087","volume":"82","author":"N Gulyaeva","year":"2017","unstructured":"Gulyaeva N. Interplay between brain BDNF and glutamatergic systems: a brief state of the evidence and association with the pathogenesis of depression. Biochem (Moscow). 2017;82:301\u20137.","journal-title":"Biochem (Moscow)"},{"key":"5627_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00541","volume":"11","author":"ZA Barandouzi","year":"2020","unstructured":"Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, Cong XS. Altered composition of gut microbiota in depression: a systematic review. Front Psychiatry. 2020;11: 541.","journal-title":"Front Psychiatry"},{"key":"5627_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00034","volume":"10","author":"SG Cheung","year":"2019","unstructured":"Cheung SG, Goldenthal AR, Uhlemann A-C, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. Front Psychiatry. 2019;10: 34.","journal-title":"Front Psychiatry"},{"key":"5627_CR84","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/j.cpr.2020.101943","volume":"83","author":"CA Simpson","year":"2021","unstructured":"Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CS. The gut microbiota in anxiety and depression\u2013a systematic review. Clin Psychol Rev. 2021;83:101943.","journal-title":"Clin Psychol Rev"},{"key":"5627_CR85","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/NDT.S243551","volume":"16","author":"S Liu","year":"2020","unstructured":"Liu S, Guo R, Liu F, Yuan Q, Yu Y, Ren F. Gut microbiota regulates depression-like behavior in rats through the neuroendocrine-immune-mitochondrial pathway. Neuropsychiatr Dis Treat. 2020;16:859\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5627_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110151","volume":"108","author":"BP Carniel","year":"2021","unstructured":"Carniel BP, da Rocha NS. Brain-derived neurotrophic factor (BDNF) and inflammatory markers: perspectives for the management of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108: 110151.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"5627_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00458","volume":"10","author":"G Arteaga-Henr\u00edquez","year":"2019","unstructured":"Arteaga-Henr\u00edquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry. 2019;10: 458.","journal-title":"Front Psychiatry"},{"issue":"5","key":"5627_CR88","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247\u201351.","journal-title":"Diabetes Care"},{"issue":"1","key":"5627_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00607-4","volume":"12","author":"C Hierro-Bujalance","year":"2020","unstructured":"Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes. Alzheimers Res Ther. 2020;12(1):1\u201313.","journal-title":"Alzheimers Res Ther"},{"key":"5627_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105158","volume":"150","author":"T Khan","year":"2021","unstructured":"Khan T, Khan S, Akhtar M, Ali J, Najmi AK. Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice. Neurochem Int. 2021;150: 105158.","journal-title":"Neurochem Int"},{"issue":"8","key":"5627_CR91","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343.","journal-title":"Hypertension"},{"issue":"1","key":"5627_CR92","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41380-020-0727-3","volume":"26","author":"T Pr\u00e9vot","year":"2021","unstructured":"Pr\u00e9vot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26(1):151\u201367.","journal-title":"Mol Psychiatry"},{"key":"5627_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121002","volume":"310","author":"AS Kamel","year":"2022","unstructured":"Kamel AS, Wahid A, Abdelkader NF, Ibrahim WW. Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1\/AMPK signaling in anxious demented rats. Life Sci. 2022;310: 121002.","journal-title":"Life Sci"},{"issue":"1","key":"5627_CR94","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psychres.2014.05.013","volume":"219","author":"BT Baune","year":"2014","unstructured":"Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression\u2013a systematic review. Psychiatry Res. 2014;219(1):25\u201350.","journal-title":"Psychiatry Res"},{"issue":"6","key":"5627_CR95","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1017\/S0033291716003123","volume":"47","author":"M Kaser","year":"2017","unstructured":"Kaser M, Zaman R, Sahakian BJ. Cognition as a treatment target in depression. Psychol Med. 2017;47(6):987\u20139.","journal-title":"Psychol Med"},{"issue":"2","key":"5627_CR96","first-page":"75","volume":"16","author":"D Marazziti","year":"2019","unstructured":"Marazziti D, Mucci F, Tripodi B, Carbone MG, Muscarella A, Falaschi V, et al. Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatr. 2019;16(2):75.","journal-title":"Clin Neuropsychiatr"},{"issue":"S1","key":"5627_CR97","first-page":"26","volume":"2020","author":"E Shimizu","year":"2020","unstructured":"Shimizu E, Takehisa Y, Bando H, Fujita M, Kusaka Y, Yuu M. Effective SGLT2 inhibitor for patient with type 2 diabetes Mellitus (T2DM) and Depression. Diabetes Res. 2020;2020(S1):26.","journal-title":"Diabetes Res"},{"issue":"5","key":"5627_CR98","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/ijph.ijph_1070_22","volume":"66","author":"IA Najar","year":"2022","unstructured":"Najar IA, Masoodi SR, Mir SA, Bhat MH, Patyar RR, Patyar S. Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: a prospective study. Indian J Public Health. 2022;66(5):41.","journal-title":"Indian J Public Health"},{"issue":"2","key":"5627_CR99","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.dsx.2022.102417","volume":"16","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2022","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Badim\u00f3n JJ. Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes Metab Syndr. 2022;16(2):102417.","journal-title":"Diabetes Metab Syndr"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05627-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:08:47Z","timestamp":1709244527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05627-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5627"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05627-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors assert that all procedures used in the conduct of this study conformed to the ethical standards of the relevant national and institutional committees on human experimentation and to the 1975 Declaration of Helsinki, as revised in 2008. The research ethics committee of Alborz University of Medical Sciences approved all procedures involving human subjects\/patients in this study with the number of the code of ethics IR.ABZUMS.REC.1400.275 and the registration code number IRCT20200805048313N1that are related to the registration of the study protocol of Iranian clinical trials. The registration date of this study is February 10, 2022. A written consent form was obtained from all participants before entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}